Hair Experts Report Varying Steroid Techniques for Alopecia
METHODOLOGY:
Researchers surveyed 28 dermatologists with hair expertise using a 77-question REDCap survey.
Participants averaged 17.7 years of experience, with completion of residency between 1985 and 2022.
The response rate was 75% (21 experts completed the survey).
The survey assessed ILC injection techniques across alopecia types, including facial alopecia.
TAKEAWAY:
For nonscarring alopecia, 5 mg/mL was the most common ILC dose (85.7%), followed by 2.5 mg/mL (38.1%); 95.2% of experts injected between 1 and 1.5 mL per session, 95.2% used a 30-gauge needle, and 95.2% injected in a grid pattern.
Most experts (71.4%) employed identical ILC techniques for both scarring and nonscarring alopecia, with 61.9% and 60%, respectively, preferring 6-week treatment intervals. The most common ILC dose for scarring alopecia was 5 mg/mL (60%), followed by 7.5 mg/mL (40%) and 10 mg/mL or more (40%).
For facial alopecia, 80% of experts used a lower concentration of 2.5 mg/mL, and 90% typically performed 3-4 sessions.
For nonscarring alopecia, experts suggested injecting parallel to the direction of hair growth to reduce pain and avoid follicle damage, and for scarring alopecia, they recommended starting with peripheral injections and moving toward the center of the lesion. For facial alopecia, experts recommended shallow injections and avoiding visible vessels to prevent atrophy and bruising.
IN PRACTICE:
'Our findings reveal general agreement amongst experts on the use of ILCs for alopecia; however, variation remains in concentration, injection spacing, and treatment duration, especially for facial and scarring alopecia,' the study authors wrote. Although a Delphi study 'could help standardize' ILC treatment approaches, they added, their results 'provide practical guidance for dermatologists on intralesional corticosteroid techniques for the treatment of various alopecia types.'
SOURCE:
This study was led by Noelle Desir, Department of Dermatology, University of Pennsylvania, Philadelphia, and was published online on June 3 in JAAD International .
LIMITATIONS:
Limitations included the hair expert identification process and potential response bias in the survey.
DISCLOSURES:
This study did not receive any funding. One study author reported serving as a consultant, advisory board member, speaker, and investigator for various pharmaceutical and cosmetic companies, including AbbVie, Arcutis Biotherapeutics, Pfizer, and L'Oréal, and also reported receiving royalties from McGraw Hill. Another author reported serving as an advisory board member for Beiersdorf. The remaining authors reported no conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...
Revenue: $545 million, a 73% year-over-year increase. Adjusted EBITDA Margin: Over 15%. Subscribers: Increased by 73,000 quarter over quarter to over 2.4 million, a 31% year-over-year growth rate. Monthly Average Revenue per Subscriber: Declined quarter over quarter to $74 from $84. Gross Margin: Expanded 3 points quarter over quarter to 76%. Cash and Short-term Investments: Over $1.1 billion at the end of the second quarter. Free Cash Flow: Negative $69 million for the second quarter. Third Quarter Revenue Guidance: Expected between $570 million to $590 million. Full Year Revenue Guidance: Expected between $2.3 billion and $2.4 billion. Full Year Adjusted EBITDA Guidance: Expected between $295 million to $335 million. Warning! GuruFocus has detected 5 Warning Sign with HIMS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hims & Hers Health Inc (NYSE:HIMS) reported a 73% year-over-year revenue growth to $545 million in Q2 2025, with an adjusted EBITDA margin exceeding 15%. The company is expanding its platform with new specialties, including hormonal health, which is expected to address significant health issues for both men and women. Hims & Hers Health Inc (NYSE:HIMS) successfully acquired ZAVA, enhancing its presence in the UK and establishing a foundation for further expansion in Europe and Canada. The company is investing in AI and technology to enhance personalized care, aiming to provide 24/7 support and improve patient engagement. Hims & Hers Health Inc (NYSE:HIMS) plans to offer lab testing as a standalone service, which is expected to empower customers with better health insights and proactive health management. Negative Points The company faced headwinds from off-boarding GLP-1 subscribers on commercially available dosages, impacting revenue recognition. There is a decline in the on-demand sexual health subscriber base, which is expected to continue affecting revenue in the short term. Hims & Hers Health Inc (NYSE:HIMS) reported a negative free cash flow of $69 million in Q2 2025 due to significant investments in inventory and working capital. The transition towards more premium daily offerings in the sexual health segment is causing temporary revenue declines. The company anticipates increased marketing and technology investments, which may pressure margins in the near term. Q & A Highlights Q: Why was now the right time to expand internationally, and what made ZAVA the right company to acquire? A: Andrew Dudum, CEO, explained that the acquisition of ZAVA is a strategic move to replicate Hims & Hers' personalized, high-touch, affordable precision medicine model in key international markets. ZAVA's ability to scale in unique regulatory environments was a key factor in the acquisition. The international market is seen as a focused effort, with a multibillion-dollar revenue opportunity in a few key markets. Q: How does the launch of at-home lab testing improve the business and support the broader mission of Hims & Hers? A: Andrew Dudum, CEO, emphasized that at-home lab testing is foundational for transitioning healthcare from treatment to prevention. It simplifies necessary tests, makes them affordable, and educates patients on optimal health metrics. This initiative is expected to open membership opportunities similar to Amazon or Costco, focusing on preventative health. Q: Can you provide insights into the core business dynamics and expectations for Q3, especially regarding the personalized GLP-1 offering? A: Oluyemi Okupe, CFO, noted material headwinds in the GLP-1 segment due to off-boarding commercially available dosages. The core business is experiencing a drag from the sexual health on-demand segment, but specialties like dermatology and weight loss are growing robustly. The transition to daily offerings in sexual health is expected to improve retention and customer lifetime value. Q: What are the expectations for the Canadian expansion and the impact of generic semaglutide pricing? A: Andrew Dudum, CEO, stated that the Canadian expansion will leverage ZAVA's expertise, with offerings under the Hims & Hers brand. The generic semaglutide is expected to be priced significantly lower than branded options, unlocking substantial market access in Canada, where a large portion of the population is affected by weight issues. Q: How is the Hers business performing, and what are the key growth drivers? A: Oluyemi Okupe, CFO, reported robust growth in the Hers business, driven by dermatology, weight loss, and mental health offerings. The upcoming launch of hormonal support for menopause is expected to further catalyze growth. Q: What is the approach to AI investments, and what impact is expected on the business? A: Andrew Dudum, CEO, highlighted a strategy focused on immediate, tactical improvements through AI. The platform's extensive patient interactions allow for rapid deployment of AI use cases, aiming to enhance efficiency and engagement across the provider, patient, and pharmacist interfaces within 3 to 6 months. Q: Can you discuss the marketing strategy and patient acquisition costs for the second half of the year? A: Oluyemi Okupe, CFO, stated that marketing investments will be robust but adhere to a capital allocation framework with a payback period of less than a year. The focus will be on specialty-specific investments and talent acquisition to support new specialties and international expansion. Q: What are the expectations for inventory levels and supply chain management? A: Oluyemi Okupe, CFO, explained that inventory levels increased to ensure a durable supply for new specialties and to leverage the strong balance sheet amid global uncertainties. This is seen as an anomaly, with future inventory adjustments expected to stabilize. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Medscape
an hour ago
- Medscape
High Lp(a) Signals Risk Beyond The Coronaries
TOPLINE: Elevated levels of lipoprotein(a) [Lp(a)] were associated with significantly increased risks for incident peripheral artery disease and carotid artery stenosis. Among patients with peripheral artery disease, those with high levels of Lp(a) (≥ 150 nmol/L) had a high risk of progressing to major adverse limb events. METHODOLOGY: Despite lifestyle interventions and therapies for lowering levels of cholesterol, a residual risk for major atherosclerotic complication persists. Researchers analyzed data from a large prospective biobank (2006-2010) to investigate whether baseline levels of Lp(a) predict the risk for onset and progression of extracoronary atherosclerotic vascular disease — a combination of peripheral artery disease and carotid artery stenosis. The UK biobank data included 460,544 individuals (average age at enrollment, 57 years; 54.2% men; 94.9% European) and followed them for a median duration of 13.6 years. Data on baseline serum levels of Lp(a) were retrieved, with levels ≥ 150 nmol/L (about 70 mg/dL) defined as high. The analysis assessed the incidence of peripheral artery disease and carotid artery stenosis and the progression to both the first major adverse limb event and first stroke. TAKEAWAY: Individuals with high levels of Lp(a) were older and more often men than those with normal levels of Lp(a) (P < .001 for both). Each 75-nmol/L (35 mg/dL) increase in levels of Lp(a) was associated with a 1.18-fold elevated risk for incident peripheral artery disease and a 1.17-fold increased risk for incident carotid artery stenosis (P < .0001 for both). Among patients with peripheral artery disease, those with high levels of Lp(a) had a 1.6-fold higher risk of developing major adverse limb events than those with normal levels of Lp(a) (P = .004). IN PRACTICE: 'Participants with established atherosclerotic vascular disease and elevated Lp(a) concentrations may represent the ideal group to benefit from targeted preventive interventions,' the researchers noted. '[The study's] findings make a strong case to explore the effect of therapies to lower Lp(a) in participants with PAD [peripheral artery disease] and carotid stenosis towards the goal of slowing disease progression and reducing major complications of amputation and stroke,' they added. SOURCE: This study was led by Tiffany R. Bellomo, MD, of Broad Institute of Harvard and MIT, Cambridge, Massachusetts. It was published online on July 28, 2025, in Circulation. LIMITATIONS: Measuring Lp(a) using immunoassays may be inaccurate for individuals with large Lp(a) isoforms. This study lacked measurement of ankle-brachial index to define peripheral arterial disease. The analysis may not have accounted for all potential confounding factors. DISCLOSURES: This study received grants from the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute. One author reported receiving research grants and personal fees from several pharmaceutical and healthcare companies and holding equity in multiple healthcare data and biotech firms. The same author reported spousal employment at a pharmaceutical company. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Are Potatoes Healthy? 3 Surprising Benefits, From Fiber to Antioxidants
Potatoes are the most commonly consumed vegetable in the U.S., yet they often get a bad rap. Most are eaten the form of fries or chips, so many people consider them an unhealthy food. It doesn't have to be that way. Eating one medium-size potato a day can be part of a healthy diet and doesn't increase cardiometabolic risk — the chances of having diabetes, heart disease or stroke — as long as the potato is steamed or baked, and prepared without adding too much salt or saturated fat, research shows. One 2020 study found that consuming non-fried potatoes also led to higher potassium and fiber intake compared to eating refined grains, like white rice, white bread or pasta. 'Certainly eating chips or french fries should be discouraged, but there are healthy ways to prepare potatoes, so I do think that lumping them all together is a little bit unfair to the poor potato,' Emily Johnston, Ph.D., study co-author, told in 2020. 'We don't want people to fear the potato, but we want to make sure that they eat it in a healthful way and in a controlled portion size.' Research on Potatoes and Health For the 2020 study, researchers looked at the effect of eating potatoes every day, compared to eating the same number of calories in refined grains. They recruited 50 healthy adults, whose baseline blood pressure and arterial stiffness were measured at the start of the study, and whose blood samples were checked for fasting glucose, cholesterol, insulin and other markers. Those checks were repeated throughout the study. The participants were then randomly assigned to replace their usual main meal starchy side dish with a study side dish: either 200 calories worth of potatoes or refined grains, as prepared by the Metabolic Diet Study Center at Penn State. They ate this way every day for four weeks. After a break of at least two weeks, they switched to the opposite study side dish, eating it with their main meal every day for a month. Potato side dishes consisted of steamed or baked red, white and gold spuds. Refined grain options included Spanish rice, pasta, garlic bread and naan, Johnston, who is now a research assistant professor in NYU's department of medicine, said. All were prepared with minimal added salt, saturated fat or sugar, though some ingredients were minimally added for taste, including scallions, onions, breadcrumbs and cheese. There was no evidence eating potatoes increased fasting glucose levels, and there was no difference in cholesterol, insulin or other markers, the authors noted. All in all, there were no adverse cardiometabolic consequences. 'We certainly want people to eat more non-starchy vegetables because we know the average American intake is well below recommendations,' Johnston said. 'But starchy vegetables and refined grains do contribute some important nutrition as well. It's just that we need to make sure we eat them in balance.' The Alliance for Potato Research and Education, a non-profit funded by the potato industry, provided money for the study, but didn't have any say in any aspects of it, the authors wrote. Potatoes Nutrition According to the U.S. Food and Drug Administration, one medium potato contains: 100 calories 26 grams carbohydrates 2 grams of fiber 3 grams of protein 0 grams of fat 1 gram of sugar 620 milligrams of potassium (18% DV) 40 milligrams vitamin C (45% DV) Health Benefits of Potatoes Potatoes are high in many vitamins and minerals and when prepared by steaming, baking or roasting with the skin on, they can be a more nutritious option than refined carbs, research has found. Potassium Potatoes are a rich source of potassium, which is important for blood pressure regulation, but most Americans don't get enough of in their diet, Johnston said. Almost half of adults in the U.S. have hypertension, according to the Centers for Disease Control and Prevention. In Johnston's 2020 study, the participants' potassium was significantly higher when they ate potatoes, compared to refined grains Their diet quality was also higher, driven by a higher vegetable intake. Fiber White potatoes can pack in a surprising amount of fiber when eaten with the skin on. A medium potato with the skin on can have 2-4 grams of fiber, according to Mayo Clinic. The fiber is both soluble and insoluble, meaning it both feeds the good bacteria in the gut and helps keep you regular. Vitamin C A medium potato can have 20-40 milligrams of vitamin C, almost half of the daily recommended amount, according to Cleveland Clinic. Your body doesn't produce vitamin C so you need to get it from your diet. This micronutrient is an antioxidant that can reduce risk of disease, boost the immune system and increase collagen production, per UCLA Health. The Healthiest Ways to Eat Potatoes Make potatoes a side dish composing about one-fourth of your whole plate, Fernstrom advised. Be careful about the portion size: One medium potato is about the size of a computer mouse, Johnston noted. Restaurant baked potatoes can be much bigger, so consider eating half. Stick to baking, roasting or steaming: Boiling potatoes doesn't add any calories or fat, but it leaches potassium out of them. Frying is a nutritional deal-breaker. Whether you bake or microwave, keep the skin on to optimize the nutrients and fiber. Skip the extras: Don't load your potato up with butter, sour cream or bacon bits. Go easy on the salt. This article was originally published on
